ClinicalTrials.gg
RecruitingNCT07781657TARBELA-ADUpdated Nov 16, 2026

Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

A Phase 2 interventional study of RO7568282 and Placebo in Alzheimer's Disease, sponsored by Hoffmann-La Roche. Recruiting at 12 sites in 5 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Now RecruitingFirst sites in 5 new countries+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Alzheimer Disease by Hoffmann-La Roche — 3 open to participants now, 8 under way, 4 of them phase 3. Alzheimer Disease · Hoffmann-La Roche.

Planned enrollment
13th of 40
450 · median 247
Started
2026
with 2 others
Phase 2
12 of 40
1 open now
Registered
40th of 40
by date

Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, this one is the 13th largest by planned enrollment, is one of 3 that started in 2026, is one of 12 in phase 2, and was the 40th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 40 studies in Alzheimer Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Alzheimer Disease by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of AD pathological process, as confirmed by either amyloid positron emission tomography (PET) scan or cerebrospinal fluid (CSF)
  • Mild cognitive impairment (MCI) or mild dementia due to AD
  • Able to swallow whole capsules
  • (BMI) within the range of 18-34 kilograms per square metre (kg/m²) (at screening)
  • Availability of an appropriate study partner

Exclusion criteria

Exclusion Criteria:

  • Any evidence of a condition other than AD that may affect cognition
  • Participants must not have unstable or cardiovascular disease within the last year, chronic uncontrolled hypertension, or clinically significant (ECG) abnormalities
  • History or presence of clinically significant cerebrovascular disease
  • Clinically significant cerebral abnormalities on magnetic resonance imaging (MRI)

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    RO7568282 High Dose

    Participants will receive high dose of RO7568282.

    Drug: RO7568282

  • Experimental
    RO7568282 Low Dose

    Participants will receive low dose of RO7568282.

    Drug: RO7568282

  • Placebo comparator
    Placebo

    Participants will receive RO7568282 matching placebo.

    Drug: Placebo

Interventions

  • DrugRO7568282

    RO7568282 will be administered as specified in the protocol.

  • DrugPlacebo

    RO7568282 matching placebo will be administered as specified in the protocol.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)

    Time frame: From baseline up to Week 72

Secondary outcomes

  1. Change From Baseline Through Week 72 in Alzheimer's Disease Assessment Scale-Cognition 13 (ADAS-Cog-13)

    Time frame: From baseline up to Week 72

  2. Change From Baseline Through Week 72 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Total Score and Instrumental Score

    Time frame: From baseline up to Week 72

  3. Incidence of Adverse Events (AEs)

    Time frame: Up to approximately Week 76

  4. Change From Baseline in Columbia-suicide Severity Rating Scale (C-SSRS)

    Time frame: From baseline up to Week 76

  5. Plasma Concentrations of RO7568282 and its Metabolite[s]

    Time frame: Up to approximately Week 76

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Nov 2029, 35 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 35 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

Start moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Aug 24, 2026
StartActual
Nov 10, 2026was Oct 2026
Primary completionEst.
Nov 1, 2029
CompletionEst.
Nov 1, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
12 sites added — first sites in United States, Australia, France, Germany and Poland. Basil Clinical is now Recruiting
Show 12 added (4 United States, 3 Poland, 2 Australia, 2 France, 1 Germany)
  • Basil Clinical · Laurelton, United States
  • Alzheimer's Research and Treatment Center · Stuart, United States
  • Alzheimer?s Research and Treatment Center · Wellington, United States
  • Conquest Research, LLC · Winter Park, United States
  • Royal Prince Alfred Hospital · Camperdown, Australia
  • Royal Melbourne Hospital · Parkville, Australia
  • Groupement Hospitalier Est - Hôpital Neurologique · Bron, France
  • Gerontopole · Toulouse, France
  • Klinikum rechts der Isar der TU München · München, Germany
  • EUROMEDIS Sp z o o · Szczecin, Poland
  • O?rodek Badawczo-Naukowo-Dydaktyczny Chorób Ot?piennych w ?cinawie · Ścinawa, Poland
  • NeuroProtect · Warsaw, Poland
across 3 updates, Oct 7, 2026 – Nov 16, 2026
Start date
Oct 31, 2026→Nov 10, 2026 (actual)
moved 2 times, Nov 6, 2026 – Nov 16, 2026
Show all 3 updates
  1. Nov 16, 2026
    5 sites added — first sites in Germany and Poland
    Show 5 added (3 Poland, 1 France, 1 Germany)
    • Gerontopole · Toulouse, France
    • Klinikum rechts der Isar der TU München · München, Germany
    • EUROMEDIS Sp z o o · Szczecin, Poland
    • O?rodek Badawczo-Naukowo-Dydaktyczny Chorób Ot?piennych w ?cinawie · Ścinawa, Poland
    • NeuroProtect · Warsaw, Poland
    Start date Nov 15, 2026→Nov 10, 2026 (now actual)
  2. Nov 6, 2026
    Not yet recruiting→Recruiting
    6 sites added — first sites in Australia and France. Basil Clinical is now Recruiting
    Show 6 added (3 United States, 2 Australia, 1 France)
    • Alzheimer's Research and Treatment Center · Stuart, United States
    • Alzheimer?s Research and Treatment Center · Wellington, United States
    • Conquest Research, LLC · Winter Park, United States
    • Royal Prince Alfred Hospital · Camperdown, Australia
    • Royal Melbourne Hospital · Parkville, Australia
    • Groupement Hospitalier Est - Hôpital Neurologique · Bron, France
    Start date Oct 31, 2026→Nov 15, 2026
    + 1 other change: verification date
  3. Oct 7, 2026
    1 site added — first site in United States
    Show site
    • Basil Clinical · Laurelton, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07781657
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Nov 10, 2026
Primary completion
Nov 1, 2029 (estimated)
Completion
Nov 1, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Reference Study ID Number: BP46554 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion